cbdMD, Inc. (NYSE American: YCBD) announced the launch of a dedicated clinical healthcare channel that will supply hemp‑derived CBD products to physicians, health systems, and value‑based care organizations. The new channel is designed to support the Centers for Medicare & Medicaid Services’ (CMS) Substance Access Beneficiary Engagement Incentive (BEI) program, which became effective on April 1 2026 and allows participating accountable‑care organizations and oncology practices to furnish eligible hemp‑derived products to Medicare patients under physician supervision.
The BEI program was expanded by CMS through operational guidance issued on March 20 2026 to include hemp‑derived cannabinoid products. Under the program, providers can supply up to $500 of eligible products per beneficiary each year, but Medicare does not reimburse these costs and beneficiaries cannot submit claims. The guidance requires that products meet federal limits on delta‑9 THC, exclude inhalable forms, and undergo third‑party testing for potency and contaminants.
cbdMD distinguishes itself by holding both OECD‑standard preclinical toxicology data and human randomized controlled trial data for its commercial lines—data that no other hemp‑derived manufacturer has publicly disclosed. The company has invested years in building a scientific and regulatory platform that meets the stringent documentation, labeling, and supply‑chain requirements of health‑system procurement, positioning it to capture a share of the nascent Medicare‑based cannabinoid market.
In its most recent quarterly report, cbdMD reported revenue of $5.02 million, beating consensus estimates of $4.96 million, and earnings per share of –$0.04 versus an estimate of –$0.06, a 33.3% beat. The revenue increase was driven by stronger demand in core segments, while the EPS improvement reflected disciplined cost management and the absence of significant one‑time charges. The company’s Q1 2026 results also highlighted improved liquidity and a reduction in operating loss compared to the prior year, underscoring the financial impact of the new channel’s early traction.
The launch places cbdMD in direct competition with other CBD brands that are also positioning themselves for the BEI program, such as Charlotte’s Web and NuLeaf Naturals. By offering a provider‑focused product line with institutional‑grade documentation, cbdMD aims to become a preferred supplier for value‑based care models that prioritize evidence‑based therapeutics, potentially unlocking new revenue streams beyond its existing direct‑to‑consumer and retail channels.
CEO Ronan Kennedy said, “Healthcare is where this category has always needed to go. This is the inflection point. CMS has established a structured, physician‑supervised framework for hemp‑derived cannabinoids within Medicare, and the bar to participate credibly is high requiring clinical data, institutional‑grade documentation and healthcare supply infrastructure. cbdMD has spent years preparing for such framework.” He added, “They require OECD‑standard toxicology, human clinical data, drug interaction transparency, and documentation that can withstand institutional review. That evidence base does not exist broadly in this category, cbdMD has built it. That is where we are focused.”
The strategic move expands cbdMD’s distribution beyond its direct‑to‑consumer and retail channels, potentially unlocking new revenue streams and strengthening its competitive position in the regulated medical space. By aligning early with the CMS BEI program, the company is poised to capture a share of a growing Medicare‑based cannabinoid market that is still in its infancy but offers significant upside as more providers seek evidence‑based therapeutic options for patients.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.